Atara Biotherapeutics (NASDAQ:ATRA) Major Shareholder Buys $670,450.00 in Stock

Key Points

• Atara Biotherapeutics' major shareholder, Innovation Ltd Panacea, acquired 55,000 shares at an average price of $12.19 per share, totaling $670,450, increasing their ownership to 1,405,000 shares.
• The company reported $0.19 earnings per share for the last quarter, significantly beating analysts' expectations of ($0.32), with revenue reaching $17.58 million.
• A significant majority, about 70.90%, of Atara Biotherapeutics' stock is currently owned by hedge funds and institutional investors, indicating strong institutional support.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) major shareholder Innovation Ltd Panacea acquired 55,000 shares of the business's stock in a transaction on Friday, August 15th. The stock was purchased at an average cost of $12.19 per share, with a total value of $670,450.00. Following the acquisition, the insider directly owned 1,405,000 shares of the company's stock, valued at $17,126,950. This represents a 4.07% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

Innovation Ltd Panacea also recently made the following trade(s):

• On Thursday, July 17th, Innovation Ltd Panacea purchased 19,335 shares of Atara Biotherapeutics stock. The shares were acquired at an average price of $9.64 per share, for a total transaction of $186,389.40.

Atara Biotherapeutics Stock Performance

NASDAQ:ATRA remained flat at $11.48 on Tuesday. 35,240 shares of the company's stock traded hands, compared to its average volume of 61,252. The firm has a market capitalization of $80.59 million, a PE ratio of -26.70 and a beta of 0.26. The stock has a fifty day moving average price of $9.92 and a two-hundred day moving average price of $8.17. Atara Biotherapeutics, Inc. has a 12 month low of $5.01 and a 12 month high of $18.70.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last released its earnings results on Monday, August 11th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.51. Atara Biotherapeutics had a net margin of 3.07% and a negative return on equity of 8.34%. The company had revenue of $17.58 million for the quarter, compared to analyst estimates of $4.23 million. Analysts forecast that Atara Biotherapeutics, Inc. will post -10.39 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Raymond James Financial Inc. acquired a new position in shares of Atara Biotherapeutics during the second quarter worth $31,000. Marshall Wace LLP acquired a new stake in Atara Biotherapeutics in the second quarter worth about $327,000. Geode Capital Management LLC lifted its holdings in Atara Biotherapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company's stock valued at $464,000 after acquiring an additional 1,457 shares during the last quarter. EcoR1 Capital LLC lifted its holdings in Atara Biotherapeutics by 7.7% in the 1st quarter. EcoR1 Capital LLC now owns 573,183 shares of the biotechnology company's stock valued at $3,405,000 after acquiring an additional 41,049 shares during the last quarter. Finally, Staley Capital Advisers Inc. lifted its stake in Atara Biotherapeutics by 60.0% during the first quarter. Staley Capital Advisers Inc. now owns 80,000 shares of the biotechnology company's stock valued at $475,000 after buying an additional 30,000 shares in the last quarter. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.